Nanoparticle and liposome formulations of doxycycline: Transport properties through Caco-2 cell line and effects on matrix metalloproteinase secretion

Biomedicine and Pharmacotherapy

Volumn 67, Issue 6, 2013, Pages 459-467

  Yücel, Çiǧdem ^a   Deǧim, Zelihagül ^b   Yilmaz, Şükran ^c  

^a ERCIYES UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c Food and Mouth Diseases Institute   (Turkey)

Author keywords

Anti tumor effect; Caco 2; Doxycycline; Liposome; MMP 2; Nanoparticle

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOXYCYCLINE; GELATINASE A; LIPOSOME; MATRIX METALLOPROTEINASE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; TAUROCHOLIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RELEASE; EMULSION; ENZYME INHIBITION; FILM; HUMAN; HUMAN CELL; HYDRATION; IN VITRO STUDY; LIPOSOMAL DELIVERY; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN SECRETION; TIGHT JUNCTION; TUMOR CELL CULTURE;

ANTI-TUMOR EFFECT; CACO-2; DOXYCYCLINE; LIPOSOME; MMP-2; NANOPARTICLE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOXYCYCLINE; EMULSIONS; HUMANS; LIPOSOMES; MATRIX METALLOPROTEINASE 2; NANOPARTICLES; P-GLYCOPROTEINS; POLYMERIZATION; TAUROCHOLIC ACID;

EID: 84880930838     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.03.001     Document Type: Article

References (78)

1. Wong E.T. Tumor growth, invasion, and angiogenesis in malignant gliomas. J Neurooncol 2006, 77:295-296.
2. Liang Q., Xiong H., Zhao Z., Jia D., Li W., Qin H., et al. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett 2009, 273:164-171.
3. Brandes A.A., Tosoni A., Franceschi E., Reni M., Gatta G., Vecht C. Glioblastoma in adults. Crit Rev Oncol Hematol 2008, 67:139-152.
4. Landeghem F.K.H., Maier-Hauff K., Jordan A., Hoffman K., Gneveckow U., Scholz R., et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 2009, 30:52-57.
5. Bernardi A., Braganhol E., Jager E., Figueiro F., Edelweiss M.I., Pohlmann A.R., et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 2009, 281(1):53-63.
6. Lino M., Merlo A. Translating biology into clinic: the case of glioblastoma. Curr Opin Cell Biol 2009, 21:311-316.
7. Yamamoto T., Nakai K., Kageji T., Kumada H., Endo K., Matsuda M., et al. Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 2009, 91:80-84.
8. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
9. Drappatz J., Wong E.T., Schiff D., Kesari S., Batchelor T., Doherty L., et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 73(1):222-227.
10. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004, 70:217-228.
11. Lefranc F., Brotchi J., Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005, 23:2411-2422.
12. Choe G., Park J.K., Jouben-Steele L., Kremen T.J., Liau L.M., Vinters H.V., et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002, 8:2894-2901.
13. Wang M., Wang T., Liu S., Yoshida D., Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20:65-72.
14. Naito Y., Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspect Med 2005, 26:379-390.
15. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neutral 2009, 8:205-216.
16. Milward E.A., Fitzsimmons C., Szklarczyk A., Conant K. The matrix metalloproteinases and CNS plasticity: an overview. J Neuroimmunol 2007, 187:9-19.
17. Acharya M.R., Venitz J., Figg W.D., Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004, 7:195-208.
18. Halvorsen B., Staff A.C., Ligaarden S., Prydz K., Kolset S.O. Lithocholic acid and sulphated lithocholic acid differ in the abilty to promote matrix metalloproteinase secretion in the human colon cancer cell line Caco-2. Biochem J 2000, 349:189-193.
19. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Alfred Yung W.K., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
20. Levin V., Phuphanich S., Glantz M.J., Mason W.P., Groves M., Recht L., et al. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proceed ASCO 2002, [21: 26a].
21. Wong E.T., Alsop D., Lee D., Tam A., Barron L., Bloom J., et al. Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. Cerebrospinal Fluid Res 2008, 5(1):1-8.
22. Onoda T., Ono T., Dhar D.K., Yamanoi A., Fujii T., Nagasue N. Doxycycline inhibits cell proliferation and invasive potential: COMBINATION therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med 2004, 143(4):207-216.
23. Clutterbuck A.L., Harris P., Allaway D., Mobasheri A. Matrix metalloproteinases in inflammatory pathologies of the horse. Vet J 2010, 183(1):27-38.
24. Castro L.J., Sahagun A.M., Diez M.J., Fernandez N., Sierra M., Garcia J.J. Pharmacokinetics of doxycycline in sheep after intravenous and oral administration. Vet J 2009, 180:389-395.
25. Vargas-Estrada D., Garcia-Mora J., Sumano H. Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. Res Vet Sci 2008, 84:477-482.
26. Wang-Gillam A., Siegel E., Mayes D.A., Hutchins L.F., Zhou Y. Anti-tumor effect of doxycycline on glioblastoma cells. J Cancer Mol 2007, 3(5):147-153.
27. Chhipa R.R., Singh S., Surve S.C., Vijayakumar M.V., Bhat M.K. Doxycycline potentiates antitumor effect of cyclophophamide in mice. Toxicol Appl Pharm 2005, 202:268-277.
28. Kroon A.M., Dontje B.H., Holtrop M., van den Bogert C. The mitochondrial genetic system as a target for chemotherapy: tetracyclines as cytostatics. Cancer Lett 1984, 25:33-40.
29. Gu Y., Lee H.M., Roemer E.J., Musacchia L., Golub L.M., Simon S.R. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 2001, 8:261-270.
30. Fife R.S., Sledge G.W. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995, 125:407-411.
31. Onoda T., Ono T., Dhar D.K., Yamanoi A., Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer 2006, 118:1309-1315.
32. Rubins J.B., Charboneau D., Alter M.D., Bitterman P.B., Kratzke R.A. Inhibition of mesothelioma cell growth in vitro by doxycycline. J Lab Clin Med 2001, 138:101-106.
33. Paemen L., Martens E., Norga K., Masure S., Roets E., Hoogmartens J., et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 1996, 52:105-111.
34. Seftor R.E., Seftor E.A., De Larco J.E., Kleiner D.E., Leferson J., Stetler-Stevenson W.G., et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998, 16:217-225.
35. Duivenvoorden W.C., Hirte H.W., Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997, 17:312-322.
36. Wang-Gillam A., Siegel E., Mayes D.A., Hutchins L.F., Zhou Y.H. Anti-tumor effect of doxycycline on glioblastoma cells. J Cancer Mol 2007, 3(5):147-153.
37. Rolain J.M., Boulos A., Mallet M.N., Raoult D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 2005, 49:2673-2676.
38. Rolain J.M., Mallet M.N., Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with coxiella burnetii endocarditis. J Infect Dis 2003, 188:1322-1325.
39. Lim H.J., Cho E.C., Shim J., Kim D.H., An E.J., Kim J. Polymer-associated liposomes as a novel delivery system for cyclodextrin-bound drugs. J Colloid Interface Sci 2008, 320:460-468.
40. Tafaghodi M., Jaafari M.R., Tabassi S.A.S. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm 2006, 64:138-145.
41. Lopez-Pinto J.M., Gonzalez-Rodriguez M.L., Rabasco A.M. Effect of cholesterol on dermal delivery from DPPC liposomes. Int J Pharm 2005, 298:1-12.
42. Gulati M., Grover M., Singh S., Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 1998, 165:129-168.
43. Drulis-Kawa Z., Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm 2010, 387(1-2):187-198.
44. 3-O-toluyl-fluorouracil-loaded liposomes. Int J Pharm 2008, 353:243-250.
45. Chung T.W., Yang M.C., Tsai W.J. A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs influences of the surface properties of liposomes and the crosslinked fibrin network. Int J Pharm 2006, 311:122-129.
46. Pavelic Z., Skalko-Basnet N., Jalsenjak I. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int J Pharm 2005, 301:140-148.
47. Joshi M.D., Müler R.H. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009, 71:161-172.
48. Johnston M.J.W., Edwards K., Karlsson G., Cullis P.R. Influence of drug-to-lipid ration on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Lip Res 2008, 18:145-157.
49. Alam M.N., Ahmad F.J., Sultana Y., Iqbal Z., Aqil M., Ali A. Development and characterization of liposome-based formulation of amiloride hydrochloride. J Disp Sci Tech 2008, 29:415-420.
50. Liu G., Garret M.R., Men P., Zhu X., Perry G., Smith M.A. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica Biophysica Acta 2005, 1741:246-252.
51. Kreuter J. Nanoparticles a historical perspective. Int J Pharm 2007, 331:1-10.
52. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009, 86(3):215-223.
53. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood-brain barier (BBB) translocation: a way to deliver drugs to the brain?. Int J Pharm 2005, 298:274-292.
54. Gan L.L., Thakker D.R. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Del Rev 1997, 23:77-98.
55. Gharat L., Taneja R., Weerapreeyakul N., Rege B., Polli J., Chikhale P.J. Targeted drug delivery systems 6: intracellular bioreductive activation, uptake and transport of an anticancer drug delivery system across intestinal Caco-2 cell monolayers. Int J Pharm 2001, 219:1-10.
56. Ranaldi G., Consalvo R., Sambuy Y., Scarino M.L. Permeability characteristics of parental and clonal human intestinal Caco-2 cell lines differentiated in serum-supplemented and serum-free media. Toxicol In Vitro 2003, 17:761-767.
57. Fogh J., Fogh J., Orfeo T. One hundred and twenty seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977, 59:221-226.
58. Tammela P., Laitinen L., Galkin A., Wennberg T., Heczko R., Vuorela H., et al. Permeability characteristics and membrane affinity of flavanoids and alkyl gallates in Caco-2 cells and in phospholipid vesicles. Arc Biochem Biophys 2004, 425:193-199.
59. Fossati L., Dechaume R., Hardillier E., Chevillon D., Prevost C., Bolze S., et al. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm 2008, 360:148-155.
60. Kardos P., Doucette K., Strab R., Furlong M., Bhoopathy S., Hidalgo I. Can Caco-2 monolayers be used to estimate blood-brain barrier permeation potential?. AAPSJ 2004, 6:S2.
61. Hellinger E., Veszelka S., Tóth A., Walter F., Kittel Á., Bakk M.L., et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2 and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 2012, 82:340-351.
62. Roomi M.W., Monterrey J.C., Kalinovsky T., Rath M., Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 2009, 21(5):1323-1333.
63. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids (1965). J Mol Biol 2009, 13:238-252.
64. Lopedota A., Trapani A., Cutrignelli A., Chiarantini L., Pantucci E., Curci R., et al. The use of Eudragit-RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur J Pharm Biopharm 2009, 72:509-520.
65. Yeh Y.H., Hwang D.F. High performance liquid chromatographic determination for bile components in fish, chicken, duck. J Chromatogr B: Biomed Sci App 2001, 751:1-8.
66. Othman A.A., Syed S.A., Newman A.H., Eddington N.D. Transport, metabolism and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharm Exp Ther 2007, 320:344-353.
67. Ingels F., Deferme S., Destexhe E., Oth M., Van den Mooter G., Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int J Pharm 2002, 232:183-192.
68. Beck R.C.R., Pohlmann A.R., Hoffmeister C., Gallas M.R., Collnot E., Svhaefer E.F., et al. Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. Eur J Pharm Biopharm 2007, 67:18-30.
69. Lasic D.D. Novel applications of liposomes. Tibtech 1998, 16:307-321.
70. Misra R., Acharya S., Dilnawaz F., Sahoo S.K. Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(e{open}-caprolactone) nanoparticle. Nanomedicine 2009, 4(5):519-530.
71. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., et al. In vitro models for the blood-brain barriers. Toxicol In Vitro 2005, 19:299-334.
72. Wang Q., Rager J.D., Weinstein K., Kardos P.S., Dobson G.L., Li J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 2005, 288:349-359.
73. Deǧim Z., Mutlu N.B., Yi{dotless}lmaz Ş., Eşsiz D., Nacar A. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie 2010, 65:32-40.
74. Mutlu N.B., Deǧim Z., Yi{dotless}lmaz Ş., Eşsiz D., Nacar A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm 2011, 37(7):775-789.
75. Boulenc X., Marti E., Joyeux H., Roques C., Berger Y., Fabre G. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. Biochem Pharmacol 1993, 46:1591-1600.
76. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Com 1991, 175:880-885.
77. Lundquist S., Renftel M., Brillault J., Fenart L., Cecchelli R., Dehouck M.P. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res 2002, 19:976-991.
78. Medina C., Jurasz P., Santos-Martinez M.J., Jeong S.S., Mitsky T., Chen R., et al. Platelet aggregation-induced by Caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 2006, 317(2):739-745.